Go Pro
→ Trump's New Dollar (From Porter & Company) (Ad)tc pixel
NYSEAMERICAN:MAIA

MAIA Biotechnology Q3 2025 Earnings Report

MAIA Biotechnology logo
$1.46 +0.02 (+1.03%)
As of 01:00 PM Eastern
This is a fair market value price provided by Massive. Learn more.
ProfileEarnings History

MAIA Biotechnology EPS Results

Actual EPS
-$0.27
Consensus EPS
-$0.19
Beat/Miss
Missed by -$0.08
One Year Ago EPS
N/A

MAIA Biotechnology Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

MAIA Biotechnology Announcement Details

Quarter
Q3 2025
Date
11/7/2025
Time
Before Market Opens
Conference Call Date
Friday, November 7, 2025
Conference Call Time
4:00PM ET

Upcoming Earnings

MAIA Biotechnology's Q2 2026 earnings is estimated for Monday, August 10, 2026, based on past reporting schedules, with a conference call scheduled at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Conference Call Resources

Powered by Quartr

Earnings Documents

MAIA Biotechnology's Q3 2025 Quarterly ReportQuarterly Report
(10-Q)

MAIA Biotechnology Earnings Headlines

MAIA Biotechnology Completes International Enrollment in Part C of Phase 2 THIO-101 Expansion Trial in Third-Line Non-Small Cell Lung Cancer
June 25, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/25/3317503/0/en/maia-biotechnology-completes-international-enrollment-in-part-c-of-phase-2-thio-101-expansion-trial-in-third-line-non-small-cell-lung-cancer.html
MAIA Biotechnology (NYSEAMERICAN:MAIA) Shares Up 0.7% - Time to Buy?
June 25, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30859471
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no debate, no vote, one executive order. Gold tripled within three years and climbed 20x over the following decade. Trump holds that same executive authority today, and his advisors are openly saying a reversal is on the table. There are two ways this plays out - both move gold in the same direction. A free briefing breaks down exactly what Nixon did, why Trump is positioned to act, and how to move your 401k into gold before any announcement - tax free.tc pixel
July 6 at 1:00 AM  |  Reagan Gold Group (Ad)
MAIA Gains on Setting up New Site
June 20, 2026  |  baystreet.cahttps://www.baystreet.ca/stockstowatch/23508/MAIA-Gains-on-Setting-up-New-Site
MAIA activates new site for THIO-101 phase II trial
June 20, 2026  |  msn.comhttps://www.msn.com/en-us/science/biology/maia-activates-new-site-for-thio-101-phase-ii-trial/ar-AA265u0j
MAIA Biotechnology Opens Enrollment for Phase 2 Expansion Trial of Novel Telomere-Targeting Agent at Winship Cancer Institute of Emory University
June 18, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/18/3314176/0/en/maia-biotechnology-opens-enrollment-for-phase-2-expansion-trial-of-novel-telomere-targeting-agent-at-winship-cancer-institute-of-emory-university.html
See More MAIA Biotechnology Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like MAIA Biotechnology? Sign up for Earnings360's daily newsletter to receive timely earnings updates on MAIA Biotechnology and other key companies, straight to your email.

About MAIA Biotechnology

MAIA Biotechnology (NYSEAMERICAN:MAIA) is a clinical‐stage biopharmaceutical company developing a proprietary platform for site‐specific conjugation of monoclonal antibodies with diagnostic and therapeutic radioisotopes. By leveraging precision radiochemistry, the company aims to enhance the safety and efficacy profiles of antibody‐based imaging agents and targeted radiotherapeutics. Its approach is designed to deliver high‐contrast tumor visualization through PET imaging as well as focused cytotoxicity in oncology indications.

The company’s pipeline includes several antibody‐radiotracer candidates optimized for the detection of distinct tumor biomarkers, with preclinical data showing favorable targeting specificity and improved pharmacokinetics compared to conventional methods. In parallel, MAIA Biotechnology is advancing therapeutic constructs that couple monoclonal antibodies to therapeutic radioisotopes for selective tumor cell eradication. These efforts are supported by in‐house radiochemistry capabilities and collaborative research partnerships with academic institutions.

Headquartered in the United States, MAIA Biotechnology serves both domestic and international research markets and is preparing key assets for regulatory submission and first‐in‐human trials. The management team comprises industry veterans in radiopharmaceutical development and antibody engineering, and the company continues to expand its platform technology to address unmet needs in cancer diagnosis and treatment.

View MAIA Biotechnology Profile
Earnings Tools